Market Intelligence for Metabolic Disease Therapeutics and High-Purity Transporter Reagents
TarMart Solution Ecosystem & Related Targets
Complete reagent toolkit for SLC6A19 functional assays. Addressing the unique challenge of 12-transmembrane topology and accessory protein dependency.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SLC6A19 Lentivirus Premade Particles Full-length ORF (12-TM) for stable cell line construction. HEK293 Expressed, Endotoxin Controlled. |
View SLC6A19 Products |
| Accessory Complex | ACE2 Recombinant Protein Essential accessory protein for SLC6A19 surface trafficking. High Purity (>95%), Sequence Verified. |
View ACE2 Products |
| Accessory Complex | Collectrin (TMEM27) Recombinant Protein Trafficking chaperone required for B0AT1 membrane expression. HEK293 Expressed. |
View TMEM27 Products |
| Antigen | SLC6A19 Mutant Library Hartnup disorder variants (e.g., D173N, R240Q). Sequence Verified, High Purity (>95%). |
View SLC6A19 Products |
| Validator | SLC6A19 siRNA Set For knockdown verification and specificity controls. |
View SLC6A19 Products |
| Paralog Control | SLC6A18 (B0AT3) Lentivirus & Protein Renal-specific paralog for selectivity screening. Critical counter-target. |
View SLC6A18 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 12-TM Complex Membrane Topology | Lentivirus Stable Cell Line System preserves native conformation; HEK293 expression with Endotoxin <1 EU/µg |
| ACE2/Collectrin Dependency | Accessory Protein Co-expression Kits available; validated for surface trafficking assays |
| Hartnup Disorder Variant Analysis | Disease-specific Mutant Panel (Sequence Verified) for structure-function studies |
| Paralog Selectivity (SLC6A18/20) | Ortholog-specific Antibodies & Cell Lines for precise counter-screening |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cynomolgus SLC6A19 lentivirus particles available; sequence verified |
| False Positives in Uptake Assays | Validated siRNA included for target-specificity confirmation |
Live SLC6A19 R&D Tracker
Access real-time intelligence on metabolic transporter drug development:
Global Clinical Landscape & Future Outlook
The SLC6A19 (B0AT1) therapeutic landscape is expanding beyond rare genetic disorders into metabolic syndrome and hepatic indications. As a key mediator of neutral amino acid absorption in the intestine and reabsorption in the kidney, SLC6A19 represents a unique node for metabolic intervention. Current development trends indicate a shift toward tissue-specific modulation strategies—selective intestinal inhibition for obesity management versus renal targeting for Hartnup disorder. The emergence of combination therapies addressing the ACE2-SLC6A19-Collectrin complex, as well as combination with incretin mimetics (GLP-1RAs) and SGLT2 inhibitors, highlights the necessity of cell-based assays that preserve the native multiprotein complex.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Axcella Health, Emerging Biotech | Metabolic Syndrome, Obesity | Cell-based Uptake Assays (Require Lentivirus stable lines with ACE2/Collectrin) |
| Monoclonal Antibodies | Early Discovery | Metabolic Disorders | FACS Binding (Need native conformation expression) |
| Gene Silencing (siRNA/ASO) | Metabolic Focused Biotech, Emerging Platform Players | Rare Metabolic Disease (Hartnup), CKD, Hepatic Steatosis | Knockdown Validation (Need reliable siRNA & controls) |
| Gene Therapy (Rare Disease) | Academic Consortia, GeneTx | Hartnup Disorder | Mutant Functional Rescue Assays (Need disease-variant protein panel) |
| Combination Therapy (SLC6A19 + GLP-1RA/SGLT2i) | Pharma, Diabetes-focused Portfolios | Cardio-renal Metabolic Syndrome, Obesity | Dual-transporter Cell Lines (Need both SLC6A19 and SLC5A2/GLP-1R ORF lentivirus) |